Drug Approval | October 21, 2025
FDA approves Tezspire for chronic rhinosinusitis with nasal polyps
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Subscribe To Our Newsletter & Stay Updated
